Profile data is unavailable for this security.
About the company
Thor Medical ASA, formerly Nordic Nanovector ASA, is a Norway-based biopharmaceutical company. The Company is a producer and supplier of alpha-particle emitters for cancer therapy. The production process is based on separation of natural occurring radioactive decay products from thorium. The Company is utilizing alpha-emitters in radiotherapy and cancer treatments using Pb-212, which can be produced from naturally occurring isotope Thorium-232 and Lead-212. The Company has developed a proprietary technology for the manufacturing of radionuclides, primarily alpha-particle emitters from natural resources. The high energy deposition and the short range of alpha particles make it possible to eradicate cancer cells while minimizing damage to nearby healthy cells
- Revenue in NOK (TTM)100.00k
- Net income in NOK-58.91m
- Incorporated2009
- Employees13.00
- LocationThor Medical ASAKarenslyst alle 9COSLO 0278NorwayNOR
- Phone+47 22183301
- Fax+47 22580007
- Websitehttps://www.thormedical.no/
More ▼
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Curasight A/S | -67.33m | -72.71m | 1.07bn | 4.00 | -- | 40.56 | -- | -- | -1.13 | -1.13 | -1.07 | 0.3809 | -1.52 | -- | -- | -11,171,250.00 | -163.63 | -37.34 | -313.58 | -40.89 | -- | -- | -- | -- | -- | -16.54 | 0.00 | -- | -27.21 | -- | -40.76 | -- | -- | -- |
| XSpray Pharma AB (publ) | 0.00 | -230.61m | 1.08bn | 26.00 | -- | 1.57 | -- | -- | -5.96 | -5.96 | 0.00 | 15.37 | 0.00 | -- | -- | 0.00 | -29.09 | -23.48 | -30.93 | -25.08 | -- | -- | -- | -- | 5.93 | -18.44 | 0.1883 | -- | -- | -- | -58.92 | -- | -14.46 | -- |
| Nykode Therapeutics ASA | 64.11m | -104.15m | 1.24bn | 62.00 | -- | 1.32 | -- | 19.36 | -0.3089 | -0.3089 | 0.1937 | 2.88 | 0.0494 | -- | 1.91 | 461,207.30 | -8.03 | 2.32 | -8.66 | 2.60 | -- | -- | -162.46 | 8.51 | -- | -- | 0.0284 | -- | -32.73 | -- | -10.43 | -- | -1.35 | -- |
| Cantargia AB | 328.92m | 149.10m | 1.35bn | 23.00 | 10.04 | 4.25 | 8.83 | 4.10 | 0.5068 | 0.5068 | 1.33 | 1.20 | 1.41 | -- | 164.02 | 14,031,360.00 | 63.91 | -56.56 | 80.65 | -63.93 | -- | -- | 45.33 | -- | -- | 76.55 | 0.00 | -- | -- | -- | 42.27 | -- | -- | -- |
| Nightingale Health Oyj | 52.83m | -207.83m | 1.52bn | 100.00 | -- | 1.51 | -- | 28.75 | -0.3052 | -0.3052 | 0.0778 | 1.10 | 0.0568 | 0.9444 | 2.79 | 46,930.00 | -22.33 | -15.66 | -24.26 | -16.95 | 75.39 | 75.21 | -393.39 | -447.17 | 8.52 | -- | 0.0511 | -- | 7.69 | 21.38 | -5.71 | -- | -12.69 | -- |
| Solar Foods Oyj | 215.13k | -120.06m | 1.59bn | 57.00 | -- | 6.64 | -- | 7,388.84 | -0.433 | -0.433 | 0.0008 | 0.7115 | 0.0004 | -- | 0.0037 | 455.00 | -22.45 | -- | -27.05 | -- | 25,931.57 | -- | -55,808.37 | -- | -- | -7.03 | 0.5092 | -- | 275.15 | -- | -22.57 | -- | -- | -- |
| Intellego Technologies AB | 821.32m | 313.97m | 1.65bn | 65.00 | 4.75 | 2.33 | 4.81 | 2.01 | 9.81 | 9.81 | 25.91 | 20.01 | 1.28 | 10.59 | 2.32 | 12,432,400.00 | 49.11 | 17.13 | 61.64 | 23.87 | 70.97 | 58.82 | 38.23 | 21.32 | 4.11 | 5.35 | 0.0617 | -- | 42.25 | 222.71 | 14.78 | -- | -- | -- |
| Devyser Diagnostics AB | 258.71m | -26.85m | 1.81bn | 115.00 | -- | 4.97 | 1,210.96 | 6.98 | -1.52 | -1.52 | 14.66 | 20.48 | 0.5262 | 1.40 | 5.53 | 1,839,394.00 | -5.64 | -10.61 | -6.60 | -12.04 | 81.96 | 80.33 | -10.71 | -28.67 | 2.27 | -2.03 | 0.1312 | -- | 28.12 | 27.53 | -14.74 | -- | 52.54 | -- |
| BioInvent International AB | 260.89m | -345.16m | 1.85bn | 124.00 | -- | 2.54 | -- | 7.10 | -4.91 | -4.91 | 3.72 | 10.38 | 0.2614 | -- | 4.90 | 2,147,790.00 | -34.58 | -19.38 | -38.20 | -20.57 | -- | -- | -132.30 | -189.97 | 7.31 | -- | 0.0154 | -- | -37.47 | -13.77 | -29.99 | -- | 21.19 | -- |
| Thor Medical ASA | 100.00k | -58.91m | 1.91bn | 13.00 | -- | 3.98 | -- | 19,120.15 | -0.223 | -0.223 | 0.0004 | 1.36 | 0.0002 | -- | 0.0078 | 11,111.11 | -13.37 | -59.74 | -13.90 | -81.16 | -- | -- | -58,908.00 | -- | 8.78 | -- | 0.018 | -- | -- | -- | -659.00 | -- | -33.37 | -- |
| Egetis Therapeutics AB (publ) | 59.03m | -355.25m | 2.09bn | 40.00 | -- | 6.42 | -- | 35.38 | -0.9376 | -0.9376 | 0.1554 | 0.7725 | 0.0945 | 45.53 | 1.93 | 1,582,857.00 | -56.85 | -36.53 | -87.92 | -41.52 | 30.14 | 81.16 | -601.62 | -558.74 | 0.7971 | -45.06 | 0.249 | -- | -19.97 | -11.00 | -5.11 | -- | -- | -- |
| Cereno Scientific AB | 0.00 | -120.72m | 2.16bn | 5.00 | -- | 9.91 | -- | -- | -0.3987 | -0.3987 | 0.00 | 0.6572 | 0.00 | -- | -- | -- | -30.72 | -20.10 | -32.58 | -21.72 | -- | -- | -- | -- | -- | -1.94 | 0.4817 | -- | -- | -- | -106.89 | -- | 47.93 | -- |
| Diamyd Medical AB | 370.81k | -194.42m | 2.41bn | 41.00 | -- | 10.01 | -- | 6,491.90 | -1.52 | -1.52 | 0.0029 | 1.68 | 0.0013 | -- | 18.81 | 8,923.08 | -69.46 | -44.47 | -76.54 | -49.74 | -- | -- | -52,430.46 | -31,802.45 | -- | -- | 0.1628 | -- | 0.00 | -17.54 | -11.81 | -- | 38.40 | -- |
Data as of Feb 11 2026. Currency figures normalised to Thor Medical ASA's reporting currency: Norwegian Krone NOK
2.63%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Handelsbanken Fonder ABas of 31 Jan 2026 | 3.99m | 1.13% |
| DNB Asset Management ASas of 28 Nov 2025 | 2.76m | 0.78% |
| Storebrand Asset Management ASas of 30 Nov 2025 | 1.70m | 0.48% |
| Dimensional Fund Advisors LPas of 30 Nov 2025 | 726.88k | 0.21% |
| Dimensional Fund Advisors Ltd.as of 30 Nov 2025 | 147.47k | 0.04% |
| SSgA Funds Management, Inc.as of 08 Jan 2026 | 2.58k | 0.00% |
More ▼
Data from 30 Sep 2025 - 31 Dec 2025Source: FactSet Research Systems Inc.
